Eli Lilly Invests $5.3 Billion to Expand Manufacturing Capacity for Incretin Receptor Agonists
Eli Lilly and Company (NYSE: LLY) has announced a significant investment of USD 5.3 billion...
Novartis’ Atrasentan Shows Significant Reduction in Proteinuria in IgA Nephropathy Trial
Novartis AG (NYSE: NVS), a Swiss pharmaceutical company, last week presented interim results for the...
AccurEdit Therapeutics Publishes Positive Data for Gene-Edited Drug ART001 in Amyloidosis Treatment
AccurEdit Therapeutics (Suzhou) Co., Ltd., a leading gene editing therapy specialist based in China, has...
Shanghai Fosun Pharma’s FCN-159 File for Dendritic and Histiocytic Tumors Accepted by China’s NMPA
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...
China’s CDE Issues Draft Guidelines for Patient-Centric Rare Disease Drug R&D
The Center for Drug Evaluation (CDE) has issued a notification regarding the patient-centric rare disease...
CStone Pharmaceuticals Expands European Reach with Ewopharma Partnership for Sugemalimab
CStone Pharmaceuticals (HKG: 2616), a biopharmaceutical company based in China, has announced a strategic partnership...
China’s NHSA Aims to Boost Medical Insurance Reform with Sanming Model
The National Healthcare Security Administration (NHSA) has issued a notification aimed at promoting the medical...
Beijing’s Cipher Gene Secures RMB 100 Million in Series C Financing to Expand Precision Medicine Services
Cipher Gene, a Beijing-based gene big data and precision medicine service provider, has reportedly secured...
Akeso Biopharma’s Ivonescimab Approved for NSCLC Treatment in China
Akeso Biopharma (HKG: 9926), a biopharmaceutical company based in China, has announced that its bispecific...
Chinese Pharma Companies Set to Showcase Cancer Treatments at ASCO 2024
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 31...
J&J’s Tremfya Meets Primary Endpoints in Phase III Crohn’s Disease Trial
Johnson & Johnson (J&J; NYSE: JNJ) has announced that a Phase III trial for its...
Bristol Myers Squibb Invests in UK Immuno-Oncology Firm NeoPhore’s Series B Extension Round
Bristol Myers Squibb (BMS; NYSE: BMY) has participated in an oversubscribed Series B extension round...
GL Capital and SciClone Pharmaceuticals Agree to Privatization and Delisting
GL Capital and SciClone Pharmaceuticals Inc (HKG: 6600) have jointly announced an agreement to privatize...
NMPA Releases 80th Batch of Reference Drugs for Generic Quality Evaluation
The National Medical Products Administration (NMPA) has released the 80th batch of reference drugs for...
Sandoz Receives European Commission Approval for Biosimilars Wyost and Jubbonti
The European Commission (EC) has granted registration approval to Sandoz, a Switzerland-headquartered pharmaceutical company (SWX:...
Degron Therapeutics Partners with Takeda for Molecular Glue Degraders Development
Degron Therapeutics, a biopharmaceutical company based in China, has entered into a collaboration development and...
Roche’s Genentech Gets Green Light for Vixarelimab UC Clinical Trial in China
Roche (SWX: ROG)’s Genentech, a leading biotechnology company based in Switzerland, has received approval to...
RemeGen’s Disitamab Vedotin on Track for Breakthrough Designation in Muscle Invasive Bladder Cancer
RemeGen Ltd (HKG: 9995), a biopharmaceutical company based in China, has announced that its antibody-drug...
Guangzhou Boosts Innovative Drug Development with New HSA Initiatives
The Healthcare Security Administration (HSA) bureau in Guangzhou’s province has issued a notification outlining measures...
Gan & Lee Pharmaceuticals Gains Marketing Approval for Insulin Glargine in Mexico
Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced that it has...